Immunomedics discontinues its trial early – hopes for accelerated approval of Sacituzumab govitecan for mTNBC
Immunomedics- a New Jersey-based pharmaceutical company has announced to freeze its Phase III confirmatory ASCENT clinical trial of sacituzumab govitecan aimed at treating metastatic triple-negative breast cancer (mTNBC).
An independent Data Safety Monitoring Committee (DSMC) recommended they stop the trial because of “compelling evidence of efficacy.”
The company, focused on developing antibody-drug conjugates for the treatment of cancer, is waiting on the results of its resubmission of accelerated approval of the drug under review by the FDA. The co...
